Biogen reported $9.94B of revenue over the trailing twelve months, +1.2% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $9.94B (to Q1 2026). Net income: $1.37B, trailing twelve months to Q1 2026. Free cash flow: $2.42B, trailing twelve months to Q1 2026. Operating margin: 16%, trailing twelve months to Q1 2026.

BIIBBiogen

Healthcare

$225.73+57% 1Y

$225.73

$135.6752 weeks$228.71

BIIB as reported

Biogen reported $9.94B of revenue over the trailing twelve months, +1.2% on the year before. 11 reported series are charted on this page, each one as filed.

$9.94B

Revenue, trailing twelve months · to Q1 2026 · +1.2% against the twelve months before

Net income: $1.37B
Net income · −7.3% year on year · trailing twelve months to Q1 2026
Free cash flow: $2.42B
Free cash flow · −0.57% year on year · trailing twelve months to Q1 2026
Operating margin: 16%
Operating margin · trailing twelve months to Q1 2026

Details›

Every series Ryufin has for BIIB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$9.94B	+1.2%	Q1 2026
Net income	$1.37B	−7.3%	Q1 2026
EPS	$9.30	−8.2%	Q1 2026
Gross margin	76%	n/a	Q1 2026
Operating margin	16%	n/a	Q1 2026
Net margin	13%	n/a	Q1 2026
ROE	8.0%	n/a	Q1 2026
ROA	5.0%	n/a	Q1 2026
ROIC	6.5%	n/a	Q1 2026
Free cash flow	$2.42B	−0.57%	Q1 2026
P/E	24.3	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.